| Advances in the systemic treatment of triple-negative breast cancer |
41 |
| Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges |
27 |
| Immune-related adverse events of immune checkpoint inhibitors: a brief review |
26 |
| Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma |
22 |
| Screening for breast cancer in 2018-what should we be doing today? |
22 |
| Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review |
19 |
| Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer |
18 |
| Overcoming endocrine resistance in hormone receptor-positive breast cancer |
18 |
| Complementary and alternative medicine use in patients before and after a cancer diagnosis |
17 |
| Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus |
15 |
| Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects |
14 |
| Rates of cannabis use in patients with cancer |
14 |
| Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer |
13 |
| Rea world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort |
13 |
| ALK inhibitors, resistance development, clinical trials |
13 |
| Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer |
13 |
| Human papillomavirus-associated oropharyngeal cancer: review of current evidence and management |
12 |
| Clinical practice guidelines in breast cancer |
12 |
| Predictors of immunotherapy-induced immune-related adverse events |
11 |
| Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer |
11 |
| Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer |
11 |
| Barriers to participation in clinical trials: a physician survey |
11 |
| Connecting people with cancer to physical activity and exercise programs: a pathway to create accessibility and engagement |
10 |
| Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients? |
10 |
| Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? |
9 |
| Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach |
9 |
| Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions |
9 |
| Incidence and mortality trends and geographic patterns of follicular lymphoma in Canada |
8 |
| A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma |
8 |
| Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung |
8 |
| Evidence-based best practices for EGFR T790M testing in lung cancer in Canada |
8 |
| Computed tomography-quantified body composition predicts short-term outcomes after gastrectomy in gastric cancer |
8 |
| Radiation therapy and immunotherapy-a potential combination in cancer treatment |
8 |
| Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines |
8 |
| How can we better help cancer patients quit smoking? The London Regional Cancer Program experience with smoking cessation |
8 |
| Quality of life in pediatric cancer survivors: contributions of parental distress and psychosocial family risk |
7 |
| Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective |
7 |
| Advanced typical and atypical carcinoid tumours of the lung: management recommendations |
7 |
| Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer |
7 |
| Procarbazine, lomustine and vincristine toxicity in low-grade gliomas |
7 |
| Endocrine therapy for breast cancer in the primary care setting |
7 |
| Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients |
7 |
| A systematic review of acupuncture for chemotherapy-induced peripheral neuropathy |
7 |
| Cost-of-illness study for non-small-cell lung cancer using real-world data |
7 |
| Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis |
7 |
| Association of preoperative anemia and perioperative allogenic red blood cell transfusion with oncologic outcomes in patients with nonmetastatic colorectal cancer |
6 |
| Multidisciplinary care of breast cancer patients: a scoping review of multidisciplinary styles, processes, and outcomes |
6 |
| Canadian consensus: oligoprogressive , pseudoprogressive, and oligometastatic non-small-cell lung cancer |
6 |
| Factors influencing surgical treatment decisions for breast cancer: a qualitative exploration of surgeon and patient perspectives |
6 |
| A Canadian guideline on the use of next-generation sequencing in oncology |
6 |
